- About Us
- Disease State
Apr 7, 2018 - Apr 11, 2018PANLAR
Inova Diagnostics Receives FDA Clearance for the First Fully Automated, Random Access Calprotectin Test
JANUARAY 3, 2018 - Inova Diagnostics, a world leader in autoimmune disease diagnostic systems and reagents for the clinical laboratory, is proud to announce the clearance of QUANTA Flash® Calprotectin by the US Food and Drug Administration (FDA). QUANTA Flash Calprotectin aids in the diagnosis of inflammatory bowel disease (IBD) and helps differentiate IBD from irritable bowel syndrome (IBS). QUANTA Flash Calprotectin is one of 29 FDA cleared assays available on BIO-FLASH®, a random access chemiluminescent instrument, and can be run simultaneously with other QUANTA Flash assays. QUANTA Flash Calprotectin is the first fully automated, random access calprotectin assay available in the US.
Inova Diagnostics Launches Next Generation EIA/IFA Processor to Help Ensure Integrity of Patient Results
DECEMBER 21, 2017 - Inova Diagnostics, a worldwide leader in IVD systems and reagents for autoimmune disease in the clinical laboratory, is pleased to announce the global launch of QUANTA-Lyser® 3000.
QUANTA-Lyser 3000 is a fully automated EIA (enzyme linked immunoassay) and IFA (immunofluorescence assay) processor. QUANTA-Lyser 3000 represents the next generation of EIA and IFA processors for use in the clinical laboratory.